Bristol Myers Squibb (NYSE: BMY) reported fourth quarter 2021 earnings results today. Total revenues increased 8% year-over-year to $12 billion, driven by
Bristol-Myers Squibb Co.
-(BMY)
Bristol-Myers bets on product pipeline to beat patent issues. Is BMY a buy?
The pharma sector has been on a stable growth trajectory lately, and the trend gathered momentum when the pandemic-related emergency made companies
BMY Earnings: Key quarterly highlights from Bristol-Myers Squibb Q3 financial results
Bristol-Myers Squibb Company (NYSE: BMY) reported second-quarter 2021 earnings. Revenues increased 10% year-over-year to $11.6 billion. Net earnings attributable to Bristol Myers
BMY Earnings: Key quarterly highlights from Bristol-Myers Squibb Q1 financial results
Bristol-Myers Squibb Company (NYSE: BMY) reported first quarter 2021 earnings results today. Revenues increased 3% year-over-year to $11.1 billion. Net earnings attributable
Earnings calendar for the week of April 26
Investor sentiment was hit by the government's proposal to levy higher capital gain tax on wealthy individuals, and the market shifted to
Strong pipeline, M&A synergies to keep Bristol Myers on growth path
Bristol Myers Squibb Company (NYSE: BMY) is thriving on its multi-pronged growth plan, based on strategic acquisitions and the promising pipeline. Recently,
Bristol Myers (BMY) stock gains after Q4 results beat Street view
Bristol-Myers Squibb Company (NYSE: BMY) Thursday reported stronger-than-expected fourth-quarter results. The company's stock gained in the pre-market session soon after the announcement.
Earnings calendar for the week of February 1
In a week that saw one of the worst stock selloffs, Gamestop came under spotlight after the stock experienced unprecedented fluctuations, marked
Bristol-Myers Squibb beats in Q3, raises guidance
Bristol-Myers Squibb Company (NYSE: BMY) reported third-quarter 2020 financial results before the market opened on Thursday. The pharmaceutical company reported a 75%
Bristol Myers looks to expand cardiovascular portfolio with MyoKardia acquisition
Bristol Myers Squibb (NYSE: BMY) agreed to acquire MyoKardia Inc. (NASDAQ: MYOK) for $13.1 billion in cash. The deal, which amounts to
Highlights of Bristol-Myers Squibb Company (NYSE: BMY) Q2 2020 Earnings
https://www.youtube.com/watch?v=dYv_jstT8BY&t=18s Pharmaceutical firm Bristol-Myers Squibb Company (NYSE: BMY) reported second-quarter 2020 financial results on Thursday morning. The results were better than analysts’
Bristol-Myers Squibb Co (NYSE: BMY) Q1 2020 Earnings Call Transcript
Bristol-Myers Squibb Co (BMY) Q1 2020 earnings call dated May. 07, 2020 Corporate Participants: Timothy Power -- Vice President, Investor Relations Giovanni Caforio -- Chairman of
Visual Representation of Bristol-Myers Squibb Company (BMY) Q1 2020 earnings
Bristol-Myers Squibb Company (NYSE: BMY) reported first-quarter 2020 financial results before the regular trading hours on Thursday. The results were better than
Bristol-Myers Squibb (BMY) slips to a loss in Q4 but beats estimates
Bristol-Myers Squibb Company (NYSE: BMY) slipped to a loss in the fourth quarter of 2019 from a profit last year, due to
Bristol-Myers Squib (BMY) set to report Q4 earnings – what is in the offing?
After closing the high-value acquisition of Celgene a few months ago, Bristol-Myers Squib (NYSE: BMY) will be publishing its fourth-quarter results on
Top five merger and acquisition deals of 2019
Every year has its share of mergers and acquisitions and 2019 was no different. Several prominent companies announced their decision to team
Bristol-Myers Squibb (BMY) earnings: Q3 results beat amid strong product sales
Driven by the strong sales of leading products, earnings of Bristol-Myers Squibb (NYSE: BMY) increased in the third quarter and exceeded the
Bristol-Myers (BMY) Q3 earnings preview: New indications, pipeline to bolster recovery
Bristol-Myers Squibb (NYSE: BMY) will be publishing its September-quarter earnings Thursday before the opening bell. The bio-pharmaceutical company is expected to earn
Amgen to take over Celgene’s OTEZLA for $13.4 billion; Bristol-Myers Squibb increases share buyback plan
Bristol-Myers-Squibb (NASDAQ: BMY) announced that Amgen (NASDAQ: AMGN) will acquire Celgene's (NASDAQ: CELG) Otezla business for $13.4 billion in a cash transaction.
Bristol-Myers Q2 earnings, revenue top Street; stock dips on weak guidance
Biopharma company Bristol-Myers Squibb (NYSE: BMY) on Thursday reported higher earnings and revenues for the second quarter, The results also came in
Earnings preview: Celgene deal in focus as Bristol-Myers prepares for Q2 results
Bristol-Myers Squibb (NYSE: BMY) will be releasing its quarterly results amid growing skepticism over the planned acquisition of rival drugmaker Celgene (CELG),